OVARIAN CANCER and US

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Thursday, March 15, 2012

Endocyte jumps on plans for cancer drug candidate - Bioscience Technology (EC145 vs Doxil - re: Doxil drug shortage....)



Endocyte jumps on plans for cancer drug candidate - Bioscience Technology:

The Inquisitr


Endocyte jumps on plans for cancer drug candidate
Bioscience Technology
The study is designed to compare EC145 to the chemotherapy drug Doxil as a treatment for ovarian cancer. Enrollment stopped because of a shortage of Doxil, and the company said Tuesday that the Food and Drug Administration will allow it to import the ...
Endocyte Prepares To Restart Clinical Trials For Experimental Cancer DrugThe Inquisitr
Endocyte to seek European OK for ovarian cancer drugIndianapolis Star
Endocyte to Submit EU Conditional Marketing Authorization Applications for ...MarketWatch (press release)
Wall Street Journal -Indianapolis Business Journal
all 21 news articles »

Dr Len's Blog: More On Dichloroacetate (DCA) In Cancer Treatment including comments



More On Dichloroacetate (DCA) In Cancer Treatment

Cochrane Review - Medscape article: Specialized Care May Boost Cancer Survival - in Oncology/Hematology, Ovarian Cancer



Medical News:Specialized Care May Boost Cancer Survival - in Oncology/Hematology, Ovarian Cancer

Grants.gov - Opportunity Synopsis DOD Ovarian Cancer Outcomes Consortium Development Award posted Mar 15th



Grants.gov - Find Grant Opportunities - Opportunity Synopsis

DoD Ovarian Cancer Outcomes Consortium Development Award

Department of Defense

Synopsis


The synopsis for this grant opportunity is detailed below, following this paragraph. This synopsis contains all of the updates to this document that have been posted as of 03/15/2012 . If updates have been made to the opportunity synopsis, update information is provided below the synopsis. If you would like to receive notifications of changes to the grant opportunity click send me change notification emails . The only thing you need to provide for this service is your email address. No other information is requested.

Any inconsistency between the original printed document and the disk or electronic document shall be resolved by giving precedence to the printed document.
Document Type: Grants Notice
Funding Opportunity Number: W81XWH-12-OCRP-OCDA
Opportunity Category: Discretionary
Posted Date: Mar 15, 2012
Creation Date: Mar 15, 2012
Original Closing Date for Applications: Aug 02, 2012   
Current Closing Date for Applications: Aug 02, 2012   
Archive Date: Sep 01, 2012
Funding Instrument Type: Cooperative Agreement
Grant
Category of Funding Activity: Science and Technology and other Research and Development
Category Explanation:
Expected Number of Awards: 2
Estimated Total Program Funding: $1,280,000
Award Ceiling:
Award Floor:
CFDA Number(s): 12.420  --  Military Medical Research and Development
Cost Sharing or Matching Requirement: No

Eligible Applicants

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"   
Additional Information on Eligibility:

Agency Name

Dept. of the Army -- USAMRAA

Description

The OCRP Outcomes Consortium Development Award supports a multi-institutional research effort conducted by leading ovarian cancer researchers and consumer advocates that specifically focuses on identifying and understanding predictors of disease outcomes in ovarian cancer patients. This effort will be executed through a two-stage approach using two separate award mechanisms: this FY12 Outcomes Consortium Development Award, which will enable the consortium to lay the groundwork for the research project, including proof of concept, and the FY14 Outcomes Consortium Award, which will support the execution of the full research project.

Link to Full Announcement

If you have difficulty accessing the full announcement electronically, please contact:

301-682-5507; help@cdmrp.org CDMRP Help Desk

Synopsis Modification History

There are currently no modifications for this opportunity.

US drug shortages could continue for years : The Lancet



US drug shortages could continue for years : The Lancet

Arch Intern Med -- Abstract: Intensive Care Unit Bed Availability and Outcomes for Hospitalized Patients With Sudden Clinical Deterioration (Calgary, Alberta)



Arch Intern Med -- Abstract: Intensive Care Unit Bed Availability and Outcomes for Hospitalized Patients With Sudden Clinical Deterioration

ONLINE FIRST Intensive Care Unit Bed Availability and Outcomes for Hospitalized Patients With Sudden Clinical Deterioration

Background  Intensive care unit (ICU) beds, a scarce resource, may require prioritization of admissions when demand exceeds supply. We evaluated the effect of ICU bed availability on processes and outcomes of care for hospitalized patients with sudden clinical deterioration.

Methods  We identified consecutive hospitalized adults in Calgary, Alberta, Canada, with sudden clinical deterioration triggering medical emergency team activation between January 1, 2007, and December 31, 2009. We compared ICU admission rates (within 2 hours of medical emergency team activation), patient goals of care (resuscitative, medical, and comfort), and hospital mortality according to the number of ICU beds available (0, 1, 2, or >2), adjusting for patient, physician, and hospital characteristics (using data from clinical and administrative databases).

Results  The cohort consisted of 3494 patients. Reduced ICU bed availability was associated with a decreased likelihood of patient admission within 2 hours of medical emergency team activation (P = .03) and with an increased likelihood of change in patient goals of care (P < .01). Patients with sudden clinical deterioration when zero ICU beds were available were 33.0% (95% CI, –5.1% to 57.3%) less likely to be admitted to the ICU and 89.6% (95% CI, 24.9% to 188.0%) more likely to have their goals of care changed compared with when more than 2 ICU beds were available. Hospital mortality did not vary significantly by ICU bed availability (P = .82).

Conclusion  Among hospitalized patients with sudden clinical deterioration, we noted a significant association between the number of ICU beds available and ICU admission and patient goals of care but not hospital mortality.

index of abstracts: Gynecologic Oncology | Vol 125, Supplement 1, Pgs S1-S188, (March, 2012) | ScienceDirect.com



Gynecologic Oncology | Vol 125, Supplement 1, Pgs S1-S188, (March, 2012) | ScienceDirect.com


ABSTRACTS PRESENTED FOR THE 43RD ANNUAL MEETING OF THE SOCIETY OF GYNECOLOGIC ONCOLOGY AUSTIN, TX USA, 

(click on pdf for full paper) Gynecologic Oncology Case Reports: A Case of Endometrial Cancer in the Context of a BRCA2 Mutation and Double Heterozygosity for Lynch Syndrome



Gynecologic Oncology Case Reports | Articles in Press | ScienceDirect.com

A Case of Endometrial Cancer in the Context of a BRCA2 Mutation and Double Heterozygosity for Lynch Syndrome


In Press, Accepted Manuscript, Available online 15 March 2012
Ping Gong, Sarah Charles, Norman Rosenblum, Zoe Wang, Agnieszka K. Witkiewicz

Highlights

► Endometrial cancer with BRCA2 mutation and double heterozygosity for Lynch syndrome 
► Loss of MLH1 and PMS2 by immunohistochemical stain 
► MSH1 and MSH6 gene mutations by genomic sequencing

open access: Open science versus commercialization: a modern research conflict?



pdf: Open science versus commercialization: a modern research conflict?

 Open debate

Open science versus commercialization: a modern research c


Abstract (provisional)

Background

Efforts to improve research outcomes have resulted in genomic researchers being confronted with complex and seemingly contradictory instructions about how to perform their tasks. Over the past decade, there has been increasing pressure on university researchers to commercialize their work. Concurrently, they are encouraged to collaborate, share data and disseminate new knowledge quickly (i.e., to adopt an open science model) in order to foster scientific progress, meet humanitarian goals, and to maximize the impact of their research.

Discussion

We present selected guidelines from three countries (Canada, United States, and United Kingdom) situated at the forefront of genomics to illustrate this potential policy conflict. Examining the innovation ecosystem and the messages conveyed by the different policies surveyed, we further investigate the inconsistencies between open science and commercialization policies.

Summary

Commercialization and open science are not necessarily irreconcilable and could instead be envisioned as complementary elements of a more holistic innovation framework. Given the exploratory nature of our study, we wish to point out the need to gather additional evidence on the coexistence of open science and commercialization policies and on its impact, both positive and negative, on genomics academic research.

The complete article is available as a provisional PDF. The fully formatted PDF and HTML versions are in production.

RNA editing study under intense scrutiny : Nature News & Comment



RNA editing study under intense scrutiny 

The idea that RNA is often edited after being transcribed from DNA is a controversial one.
PASIEKA/SCIENCE PHOTO LIBRARY